GLPwatch
Obstructive sleep apnea
Approved indication
Last updated 2026-05-28 15:46 UTCZepbound (tirzepatide) is an FDA-approved GLP-1 drug for obstructive sleep apnea, and semaglutide has been evaluated in research regarding its safety profile in this context.
AI summary of the sources below.
How Obstructive sleep apnea connects
- Drugs Zepbound
- Molecules Tirzepatide
- Research 101 papers
Approved GLP-1 drugs (1)
Research (50)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies.
- Recent updates on GLP-1 agonists: Current advancements & challenges.
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- The benefits of GLP-1 drugs beyond obesity.
- Glucagon-like peptide-1 analogues: An overview.
- Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice.
- Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.
- Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.
- Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
- Glucagon-like peptide agonists: A prospective review.
- Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes.
- Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.
- GLP-1 agonists: A review for emergency clinicians.
- Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology.
- GLP-1 and Its Analogs: Does Sex Matter?
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.
- The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.
- GLP-1 as a target for therapeutic intervention.
- Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
- An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.
- Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
- An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.
- A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
- Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling.
- Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
- Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
- The Future of the GLP-1 Receptor Agonists.
- Incretin-based therapies for the treatment of obesity-related diseases.
Common questions
- Which GLP-1 drugs are FDA-approved for Obstructive sleep apnea?
- Zepbound is FDA-approved for obstructive sleep apnea.
- Is there research on GLP-1 drugs for Obstructive sleep apnea?
- GLPwatch tracks 101 research papers on GLP-1 drugs and obstructive sleep apnea. This research is investigational and does not imply FDA approval.